On­col­o­gy biotech plots ex­pe­dit­ed ap­proval for bone can­cer drug af­ter Phase 2 win

OS Ther­a­pies is mov­ing ahead with plans for an ac­cel­er­at­ed ap­proval path­way af­ter its off-the-shelf can­di­date for peo­ple who have had surgery to treat os­teosar­co­ma …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER